Phenotypic characterization of epidemic versus sporadic strains of methicillin-resistant Staphylococcus aureus.

Journal of Clinical Microbiology
W J Van WamelC M Vandenbroucke-Grauls

Abstract

Forty strains of methicillin-resistant Staphylococcus aureus (MRSA) were divided on the basis of their epidemiologic behavior into two subgroups, sporadic MRSA (SMRSA) and epidemic MRSA (EMRSA) strains. The strains were examined for binding of 125I-labelled fibronectin, vitronectin, collagen, Fc fragments of immunoglobulin G, and fibrinogen. A significant difference between EMRSA and SMRSA strains was found for binding of 125I-labelled fibrinogen and for Fc fragments of immunoglobulin G, (P < 0.05). No significant difference in the binding of 125I-labelled fibronectin and collagen was found between EMRSA and SMRSA strains. The binding of 125I-labelled vitronectin to MRSA strains was found to be aspecific. Capsular serotypes of the strains were determined with monoclonal antibodies against capsular types 5 and 8. Strains could be divided into the following four groups: types 5, 8, and 5/8 and nontypeable. More nontypeable strains were found in the EMRSA group (66.6%). Significantly more EMRSA strains (79%) than SMRSA strains (44%) produced alpha-toxin (P < 0.025). Logistic regression analysis using a combination of the parameters 125I-labelled immunoglobulin G binding, capsular type, and alpha-toxin production predicted the epid...Continue Reading

References

Apr 1, 1992·Epidemiology and Infection·P AparicioB D Cookson
Jul 1, 1990·The Journal of Hospital Infection·S KerrR R Marples
Jan 1, 1991·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·C M Vandenbroucke-GraulsJ Verhoef
Aug 1, 1988·Cell Structure and Function·T YatohgoM Hayashi
May 4, 1989·The New England Journal of Medicine·W Brumfitt, J Hamilton-Miller
Aug 1, 1988·Journal of Medical Microbiology·M A Beard-PeglerA M Vickery
Aug 1, 1987·Journal of Clinical Pathology·J I Roberts, M A Gaston
Sep 1, 1985·Journal of Clinical Microbiology·W W KarakawaJ B Robbins
Sep 15, 1984·The Medical Journal of Australia·D E TownsendW B Grubb
Mar 27, 1993·Lancet·J H WagenvoortH M Toenbreker
Oct 1, 1955·Journal of General Microbiology·E S DUTHIE
Jan 24, 1959·Lancet·R E WILLIAMS

❮ Previous
Next ❯

Citations

Apr 1, 1997·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·O G Brakstad, J A Maeland
Jan 6, 2001·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·A van Belkum
Oct 1, 1996·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·M Aires de SousaH de Lencastre
Mar 11, 2005·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Fernando ChavesJoaquín R Otero
Jan 6, 2001·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·D S BlancUNKNOWN Swiss MRSA Group
Apr 1, 1997·Journal of Clinical Microbiology·A van BelkumH Verbrugh
Mar 1, 1997·Infection and Immunity·F LundbergA Ljungh
Nov 4, 2009·Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases·Gerrit KuhnDominique S Blanc

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.